Bristol Myers Squibb to Acquire Mirati Therapeutics for $58.00/Per Share In Cash, Plus One CVR/Share Worth Up To $12/Share In Cash
Portfolio Pulse from Charles Gross
Bristol Myers Squibb (BMY) has announced a definitive merger agreement to acquire Mirati Therapeutics (MRTX) for $58.00 per share in cash, totaling $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) per share, potentially worth $12.00 per share in cash, adding an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both companies' Boards of Directors.
October 08, 2023 | 9:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb is acquiring Mirati Therapeutics, which could potentially strengthen its portfolio and market position.
The acquisition of Mirati Therapeutics by Bristol Myers Squibb could potentially strengthen its portfolio and market position, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Mirati Therapeutics is being acquired by Bristol Myers Squibb, which could result in a significant cash inflow for its stockholders.
The acquisition of Mirati Therapeutics by Bristol Myers Squibb could result in a significant cash inflow for its stockholders, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100